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ABSTRACT
Iron overload presenting as exacerbation of hepatic graft-versus-host disease (GVHD) after allogeneic
hematopoietic stem cell transplantation has not been previously described. We report 6 patients with
established hepatic GVHD in whom iron overload (median serum ferritin, 7231 g/dL; median transferrin
saturation, 77%) resulting from a lifetime median of 20 units of packed red blood cell transfusions was
manifested by worsening of liver function. Liver biopsies performed in 4 patients confirmed severe iron
overload and also hepatic GVHD. Analysis for the C282Y and H63D hemochromatosis gene mutation was
negative for the homozygous state in all 6 patients. Erythropoietin-assisted phlebotomy resulted in
normalization of liver function at a median of 7 months and of serum ferritin at a median of 11 months.
Immunosuppressive therapy was successfully tapered in all 4 patients who completed the phlebotomy
program, and this supported the impression that iron overload, rather than GVHD, was the principal cause
of liver dysfunction. At a median follow-up of 50 months (range, 18-76 months) from the transplantation
and 25 months (range, 5-36 months) from ferritin normalization, all 4 patients require maintenance
phlebotomy. We conclude that iron overload can mimic GVHD exacerbation, thus resulting in unneces-
sary continuation or intensification of immunosuppressive therapy for GVHD, and that maintenance
phlebotomy is necessary after successful iron-reduction therapy.
© 2006 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
ion (allo-SCT) is curative treatment for many pa-
ients with malignant and nonmalignant disorders.
ransfusion of large quantities of packed red blood
ells (PRBCs) during initial diagnosis, chemother-
py, and transplantation can lead to transfusion-
ssociated iron overload. In adults, transfusion-as-
ociated iron overload generally occurs with
ransfusion of more than 100 to 150 units of PRBCs
1]. Iron overload has been reported in the recipi-
nts of both autologous SCT and allo-SCT, as well
s patients receiving chemotherapy [2-9]. Lifetime
nfusion of less than 50 to 60 units of PRBCs led to p
06linically signiﬁcant iron overload in most reported
atients; increased intestinal absorption due to ep-
thelial injury related to chemotherapy or graft-
ersus-host disease (GVHD) is implicated [7,10,11].
n a patient with an established diagnosis of hepatic
hronic GVHD (cGVHD), worsening liver func-
ions are often interpreted as an exacerbation of
iver GVHD resulting in empiric intensiﬁcation of
mmunosuppressive therapy. Here we provide the
rst report of 6 patients in whom iron overload–
elated liver dysfunction was initially considered to
e cGVHD exacerbation. Additionally, the role of
aintenance phlebotomy after successful iron-de-
letion therapy is discussed.
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Iron Overload after Hematopoietic SCT
BATIENTS AND METHODS
Clinical and laboratory data of 6 patients who did
ot respond to continued or intensiﬁed hepatic cGVHD
reatment in whom iron overload presented as cGVHD
xacerbation were prospectively collected (May 2002
o September 2005). The patient characteristics are
escribed in Table 1. Medical charts were reviewed
or patient demographics, primary diagnosis, trans-
lant characteristics, and cGVHD status. Clinical or-
an system involvement including the liver, skin, heart,
nd pancreas was noted. Serial liver function tests were
erformed, including alanine aminotransferase (refer-
nce range, 7-40 IU/L), alanine aspartate transferase
reference range, 7-40 IU/L), alkaline phosphatase (ref-
rence range, 50-136 IU/L), total bilirubin (reference
ange, 0.3-1.2 mg/dL), albumin (reference range, 3.4-5.0
/dL), and prothrombin time (reference range, 9.5-12
econds). Serum ferritin (reference range, 10-240 g/L),
ransferrin saturation (reference range, 20%-55%),
umber of PRBC transfusions, and time to ferritin
ormalization assessed iron status. Transjugular liver
iopsy, performed in 4 patients, was uncomplicated. Pre-
ransplantation stored DNA samples or DNA samples
rom buccal mucosa were used to exclude hereditary
emochromatosis gene mutations (H63D and C282Y)
n all 6 patients.
Clinically signiﬁcant iron overload was deﬁned as
vidence of hepatic dysfunction attributed to excess
ron deposition with serum ferritin levels of 1000
g/L [12-14]. Patients were evaluated for viral hepa-
itis. Chronic GVHD was classiﬁed as extensive or
imited [15]. Treatment of cGVHD included a com-
ination of prednisone, cyclosporine, or tacrolimus
nd mycophenolate sodium (CellCept; Roche Phar-
aceuticals, Nutley, NJ) in variable dosage. Phlebot-
my was performed by using a venesection kit (Baxter
ealth Corporation, Deerﬁeld, IL). With each phle-
otomy, approximately 350 to 500 mL of whole blood
as removed. Phlebotomies were repeated every 1 to
weeks until serum ferritin normalized (phlebotomy
rogram). Once normal serum ferritin levels were
chieved, maintenance phlebotomy was performed ev-
ry 3 to 6 months to maintain serum ferritin in the low
ormal range (10-40 g/L) [16]. The complete blood
ount was checked before each phlebotomy, and the
rocedure was not performed if the hemoglobin
as 11 g/dL. Recombinant erythropoietin in the
orm of either darbepoetin (Aranesp, Amgen Inc.,
housand Oak, CA) 200 g subcutaneously every 2
eeks or epoetin alfa (Procrit, Ortho Biotech Prod-
cts, LP, Raritan, NJ) 40 000 IU subcutaneously
eekly was used intermittently to facilitate planned
hlebotomy. Erythropoietin therapy was initiated for
emoglobin levels 11 g/dL and was discontinued at
2 g/dL. The institutional review board approved the
tudy.
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5ESULTS
Tables 1 and 2 describe patient characteristics and
esponses to phlebotomy. The median time to clinical
anifestations of iron overload from transplantation
as 15 months (range, 6-35 months). The last trans-
usion preceding the diagnosis of iron overload oc-
urred at a median of 8 months (range, 4-33 months).
ifetime PRBC transfusion data were incomplete in 1
atient; 5 patients received a median of 20 units of
RBC transfusion (range, 16-46 units). Analysis of
282Y and H63D hemochromatosis genes from pre-
ransplantation DNA samples (n  4) and buccal mu-
osa (n  2) revealed no mutations in 4 patients. One
atient was heterozygous for both the C282Y and
63D genotypes; another patient was heterozygous
or H63D but not for C282Y.
Apart from abnormal liver function tests, the clin-
cal manifestations of iron overload included bronze
kin (n  6), glucose intolerance (n  4), and hepatic
ncephalopathy and ascites (n  2; patients 1 and 2).
ardiac status, evaluated in 4 patients with 3-dimen-
ional echocardiography, was normal. Liver biopsy in
patients revealed hepatic GVHD, along with a
arked iron deposition in the Kupffer cells, macro-
hages, and periportal hepatocytes, with a varied de-
ree of ﬁbrosis. One patient (No. 1) had advanced
irrhosis. In 2 patients (Nos. 3 and 5) in whom liver
iopsy was not performed, improvement in organ
unction with iron-reduction therapy (in the absence
f other speciﬁc therapy) strongly suggested iron
verload. The most severe liver dysfunction beyond
ay 100 after allo-SCT was observed at a median of
60 days (range, 180-1060 days). The hepatitis proﬁle
as negative at the diagnosis of iron overload; 1 pa-
ient (No. 3) developed hepatitis B after successful
ron depletion. All patients had cGVHD (limited, n 
; extensive, n  1). The liver function abnormality
ersisted despite continued or intensiﬁed immunosup-
ressive therapy in all patients. The median time to
uccessful ferritin normalization with weekly or bi-
eekly phlebotomy was 11 months (range, 8-14
onths) in the 4 patients who completed the phlebot-
my program (Figure 1). The median time to liver
unction normalization was 7 months (range, 2-12
onths). Baseline median hemoglobin levels before
hlebotomy were 14.5 g/dL (12.3-16.5 g/dL), and
hey decreased to 12 g/dL (10.9-13.8 g/dL) during
hlebotomy. The median hemoglobin concentration
t ferritin normalization (n  4) was 14.1 g/dL (13.1-
4.9 g/dL).
Immunosuppressive therapy was discontinued
ithout worsening of liver functions in all 4 patients
ho completed the phlebotomy program. Two pa-
ients continued phlebotomy for 6 and 12 months. At
edian follow-up of 50 months (range, 17-74 months)rom transplantation and 25 months (range, 5-36
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Iron Overload after Hematopoietic SCT
Bonths) after successful ferritin normalization, all 4
atients require maintenance phlebotomy every 3 to 6
onths to maintain ferritin 40 g/dL. Figure 2
llustrates ferritin increases in 3 patients after ferritin
ormalization (1 patient [No. 4] completed the phle-
otomy program only 3 months before this writing).
ne patient died of extensive cGVHD and chronic
espiratory failure 19 months after ferritin normaliza-
ion.
ISCUSSION
Apart from hepatocellular, cardiac, and other or-
an dysfunction [16], iron overload may worsen the
atural course of liver GVHD, similar to that of
hronic hepatitis, and its response to therapy [17,18].
ron overload also increases the risk of opportunistic
nfections in immunocompromised patients, includ-
ng Yersinia enterocolitica, Vibrio vulniﬁcus, and Listeria
onocytogenes infections, aspergillosis, and mucormy-
oses [19]. Although acute inﬂammation [20], vitamin
deﬁciency [21], and liver disease [12] inﬂuence se-
um ferritin, it provides a simple noninvasive means to
ssess body iron stores [5,8,13,16]. Hyperferritinemia
s a common late effect of hematopoietic transplanta-
ion, with a reported incidence of 88% [2]. Most
atients, however, do not develop clinical evidence of
ron overload. Moreover, serum ferritin declines with
ime [5,8,17,22], and therapeutic phlebotomy for
hemical hyperferritinemia [8,9] cannot be justiﬁed.
lso in these reports, the distinction between chemical
yperferritinemia and clinically signiﬁcant iron over-
oad (excess iron leading to organ dysfunction) is lack-
ng [8,9]. Confounding factors in the form of viral
epatitis (25%-50% incidence in some series) also
nterfere with interpretation of both liver function and
erum ferritin results [2,4]. Iron overload has been
igure 1. Time to serum ferritin normalization in 4 patients who
ompleted the phlebotomy program.eported in the recipients of both autologous SCT and p
B&MTllo-SCT, as well as in patients receiving chemother-
py [2-9]. It is interesting to note that lifetime infusion
f 50 to 60 units of PRBCs has led to clinically
igniﬁcant iron overload in most reported patients. Its
s speculated that intestinal absorption is increased as
result of epithelial injury related to chemotherapy or
VHD [7,10,11].
In our patients, erythropoietin support allowed
ninterrupted phlebotomy by preventing iatrogenic
nemia and may have mobilized stored iron. The most
rofound manifestations of iron overload were seen in
he ﬁrst 2 patients and included ascites and grade 2
epatic encephalopathy. Early recognition in the sub-
equent 4 patients may have prevented such an ad-
anced presentation. Although steroids and immuno-
uppression therapy with cyclosporine and tacrolimus
an account for hyperglycemia and glucose intoler-
nce in these patients, hyperglycemia persisted despite
heir tapering or discontinuation. After successful iron
epletion, however, all 4 patients had normal blood
lucose levels. Hemochromatosis gene analysis was
egative for the homozygous state of both the C282Y
nd H63D genotypes. Because further genetic studies
or other mutations were not performed, genetic pre-
isposition in these patients cannot be completely
uled out.
Gradual ferritin elevation after successful iron de-
letion (Figure 2) is fascinating. In the absence of oral
ron supplementation, transfusion, inﬂammation, or
bnormal liver functions, ferritin elevation is likely
ue to increased gastrointestinal absorption of bio-
vailable iron in meals, somewhat similar to that in
rimary hemochromatosis. The gastrointestinal mu-
osal dysfunction related to cGVHD [10], mucosal
njury related to previous chemotherapy treatments
7,11], and/or alteration in hepcidin regulation [23]
ay explain the increased iron absorption. Such reac-
umulation, along with iron overload with merely 20
igure 2. Ferritin elevation after serum ferritin normalization in 4
atients who completed the phlebotomy program.
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5nits (median) of PRBC transfusion in our patient,
ay also the indicate potential role of GVHD in iron
ysregulation. Chronic liver disease (cGVHD)–related
ncreased gastrointestinal iron absorption in these pa-
ients might explain the need for maintenance phle-
otomy after successful iron depletion [24].
Prospective well-designed studies are necessary to
stimate the prevalence of clinically signiﬁcant iron
verload and to establish guidelines for screening in
llo-SCT recipients. Such studies will deﬁne the role
f routine screening with serum ferritin and the eval-
ation of hepatic iron load with noninvasive magnetic
esonance imaging [25] and will identify a subgroup of
atients who may beneﬁt from currently available oral
helating agents [26,27]. We recommend serum fer-
itin estimation in all patients with unexplained ab-
ormal liver functions and routine screening 6 to 12
onths after transplantation. We conclude that iron
verload can manifest as GVHD exacerbation result-
ng in unnecessary continuation or intensiﬁcation of
mmunosuppressive therapy and that maintenance
hlebotomy is necessary after initial iron-reduction
herapy to maintain normal ferritin values.
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